CN101778850A - 杂芳基酰胺类似物 - Google Patents

杂芳基酰胺类似物 Download PDF

Info

Publication number
CN101778850A
CN101778850A CN200880021498A CN200880021498A CN101778850A CN 101778850 A CN101778850 A CN 101778850A CN 200880021498 A CN200880021498 A CN 200880021498A CN 200880021498 A CN200880021498 A CN 200880021498A CN 101778850 A CN101778850 A CN 101778850A
Authority
CN
China
Prior art keywords
indole
alkyl
pyrimidin
methyl
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880021498A
Other languages
English (en)
Chinese (zh)
Inventor
R·巴克塔瓦查拉姆
D·C·伊尔
S·M·卡皮托斯蒂
D·J·武斯特罗
J·原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN101778850A publication Critical patent/CN101778850A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN200880021498A 2007-08-10 2008-08-11 杂芳基酰胺类似物 Pending CN101778850A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95525007P 2007-08-10 2007-08-10
US60/955,250 2007-08-10
PCT/US2008/072760 WO2009023623A1 (en) 2007-08-10 2008-08-11 Heteroaryl amide analogues

Publications (1)

Publication Number Publication Date
CN101778850A true CN101778850A (zh) 2010-07-14

Family

ID=40351102

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880021498A Pending CN101778850A (zh) 2007-08-10 2008-08-11 杂芳基酰胺类似物

Country Status (14)

Country Link
EP (1) EP2185560A4 (enExample)
JP (2) JP2010535816A (enExample)
KR (1) KR20100066422A (enExample)
CN (1) CN101778850A (enExample)
AU (1) AU2008286946B2 (enExample)
BR (1) BRPI0812594A2 (enExample)
CA (1) CA2691512A1 (enExample)
CO (1) CO6251319A2 (enExample)
EA (1) EA020332B1 (enExample)
IL (1) IL202550A0 (enExample)
NZ (1) NZ582056A (enExample)
SG (1) SG183699A1 (enExample)
UA (1) UA99729C2 (enExample)
WO (1) WO2009023623A1 (enExample)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104854087A (zh) * 2012-12-18 2015-08-19 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的吲哚羧酰胺衍生物
CN104918946A (zh) * 2013-01-22 2015-09-16 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
CN105209464A (zh) * 2013-03-14 2015-12-30 詹森药业有限公司 P2x7调节剂
CN105636646A (zh) * 2013-07-17 2016-06-01 全球结核病药物研发联盟 氮杂吲哚化合物、其合成及其使用方法
US9540388B2 (en) 2013-03-14 2017-01-10 Janssen Pharmaceutica Nv P2X7 modulators
CN106478662A (zh) * 2012-07-17 2017-03-08 武田药品工业株式会社 5‑ht3受体拮抗剂
US9604982B2 (en) 2013-03-14 2017-03-28 Janssen Pharmaceutica Nv P2X7 modulators
US10047092B2 (en) 2013-03-14 2018-08-14 Janssen Pharmaceutica Nv Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
US10150766B2 (en) 2014-09-12 2018-12-11 Janssen Pharmaceutica Nv P2X7 modulators
US10329306B2 (en) 2014-09-29 2019-06-25 Takeda Pharmaceutical Company Limited Crystalline form of 1-(1-methyl-1H-pyrazol-4-yl)-N-((IR,5S,7S)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1H-indole-3-carboxamide
WO2022062991A1 (zh) * 2020-09-22 2022-03-31 苏州恩华生物医药科技有限公司 吲哚衍生物及其应用
US11597728B2 (en) 2018-09-28 2023-03-07 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
WO2023198199A1 (zh) * 2022-04-15 2023-10-19 先声再明医药有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂
US11820766B2 (en) 2018-09-28 2023-11-21 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
US11839663B2 (en) 2019-09-30 2023-12-12 Janssen Pharmaceutica Nv Radiolabelled MGL pet ligands
US11891387B2 (en) 2020-03-26 2024-02-06 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
US12338243B2 (en) 2014-09-12 2025-06-24 Janssen Pharmaceutica Nv P2X7 modulators

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2243772T3 (da) * 2009-04-14 2012-02-13 Affectis Pharmaceuticals Ag Hidtil ukendte P2X7R-antagonister og deres anvendelse
WO2012110190A1 (en) * 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
PT2707101T (pt) 2011-05-12 2019-05-30 Proteostasis Therapeutics Inc Reguladores da proteostase
WO2012163792A1 (en) * 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) * 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
ES2574840T3 (es) 2011-07-22 2016-06-22 Actelion Pharmaceuticals Ltd. Derivados de amidas heterocíclicas como antagonistas de receptores p2x7
KR102033190B1 (ko) * 2012-01-20 2019-10-16 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 헤테로시클릭 아미드 유도체
EA029644B1 (ru) * 2012-12-12 2018-04-30 Идорсиа Фармасьютиклз Лтд Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
CA2896790C (en) 2013-01-22 2022-05-10 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
MD20150071A2 (ro) 2013-02-19 2016-02-29 Pfizer Inc. Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US10131669B2 (en) 2014-07-24 2018-11-20 Pfizer Inc. Pyrazolopyrimidine compounds
HUE044040T2 (hu) 2014-08-06 2019-09-30 Pfizer Imidazopiridazin vegyületek
CN107207476B (zh) * 2014-12-15 2021-03-19 默克专利有限公司 吲哚和氮杂吲哚衍生物及其用于神经退化性疾病中的用途
JP6462493B2 (ja) 2015-05-29 2019-01-30 株式会社デンソー 進入判定装置、進入判定方法
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
TW201819361A (zh) 2016-09-03 2018-06-01 印度商托仁特生技有限公司 新穎吲唑化合物

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374846A (en) * 1979-08-02 1983-02-22 Kali-Chemie Pharma Gmbh N-Amino alkyl indole compounds compositions containing same, and a method of using same in therapy of disorders of gastrointestinal motility
US4803198A (en) * 1981-08-08 1989-02-07 Kali-Chemie Pharma Gmbh 1-Phenyl-2-aminocarbonylindole compounds, preparation thereof and pharmaceutical compositions containing them
CN1082318A (zh) * 1992-06-05 1994-02-23 国际壳牌研究有限公司 杀真菌的吲哚衍生物
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
CN1353702A (zh) * 1999-04-09 2002-06-12 阿斯特拉曾尼卡有限公司 金刚烷衍生物
US20030203909A1 (en) * 2000-08-09 2003-10-30 Hiroyuki Ushio Fused bicyclic amide compounds and medicinal use thereof
WO2004056768A2 (en) * 2002-12-20 2004-07-08 Bayer Healthcare Ag Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
US20050020593A1 (en) * 2003-07-24 2005-01-27 Aventis Pharma Aryl-heteroaromatic compounds, compositions comprising them and use
CN1589270A (zh) * 2001-11-22 2005-03-02 安万特医药德国有限公司 作为因子Xa抑制剂的吲哚－2－甲酰胺化合物
US20050165049A1 (en) * 2004-01-23 2005-07-28 Christopher Hulme Vanilloid receptor ligands and their use in treatments
CN101010297A (zh) * 2004-08-05 2007-08-01 赛诺菲-安万特 N－(1h－吲哚基)－1h－吲哚－2－羧酰胺衍生物，它们的制备方法和药用用途
CN101115718A (zh) * 2005-01-07 2008-01-30 赛诺菲-安万特 N-(杂芳基)-1h-吲哚-2-甲酰胺衍生物及其作为辣椒素trpv1受体配位体的用途
CN101151246A (zh) * 2005-03-21 2008-03-26 欧加农股份有限公司 1-苄基吲哚-2-甲酰胺衍生物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2557342A1 (de) * 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
HU227568B1 (en) * 1997-12-24 2011-08-29 Sanofi Aventis Deutschland Indole derivatives, as inhibitors os factor xa
ATE396978T1 (de) * 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
US6653304B2 (en) * 2000-02-11 2003-11-25 Bristol-Myers Squibb Co. Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
BR0211810A (pt) * 2001-08-09 2004-08-24 Ono Pharmaceutical Co Derivados ácido carboxìlico e agente farmacêutico compreendendo os mesmos como ingrediente ativo
ATE374768T1 (de) * 2002-10-03 2007-10-15 Hoffmann La Roche Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren
DE10253426B4 (de) * 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
US20070213359A1 (en) * 2005-12-30 2007-09-13 Acadia Pharmaceuticals Inc. Bicyclic-nitrogen compounds as modulators of ghrelin receptor and uses thereof
MX2008010671A (es) * 2006-02-21 2008-10-01 Amgen Inc Derivados de cinolina como inhibidores de fosfodiesterasa 10.

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374846A (en) * 1979-08-02 1983-02-22 Kali-Chemie Pharma Gmbh N-Amino alkyl indole compounds compositions containing same, and a method of using same in therapy of disorders of gastrointestinal motility
US4803198A (en) * 1981-08-08 1989-02-07 Kali-Chemie Pharma Gmbh 1-Phenyl-2-aminocarbonylindole compounds, preparation thereof and pharmaceutical compositions containing them
CN1082318A (zh) * 1992-06-05 1994-02-23 国际壳牌研究有限公司 杀真菌的吲哚衍生物
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
CN1353702A (zh) * 1999-04-09 2002-06-12 阿斯特拉曾尼卡有限公司 金刚烷衍生物
US20030203909A1 (en) * 2000-08-09 2003-10-30 Hiroyuki Ushio Fused bicyclic amide compounds and medicinal use thereof
CN1589270A (zh) * 2001-11-22 2005-03-02 安万特医药德国有限公司 作为因子Xa抑制剂的吲哚－2－甲酰胺化合物
WO2004056768A2 (en) * 2002-12-20 2004-07-08 Bayer Healthcare Ag Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
US20050020593A1 (en) * 2003-07-24 2005-01-27 Aventis Pharma Aryl-heteroaromatic compounds, compositions comprising them and use
US20050165049A1 (en) * 2004-01-23 2005-07-28 Christopher Hulme Vanilloid receptor ligands and their use in treatments
CN101010297A (zh) * 2004-08-05 2007-08-01 赛诺菲-安万特 N－(1h－吲哚基)－1h－吲哚－2－羧酰胺衍生物，它们的制备方法和药用用途
CN101115718A (zh) * 2005-01-07 2008-01-30 赛诺菲-安万特 N-(杂芳基)-1h-吲哚-2-甲酰胺衍生物及其作为辣椒素trpv1受体配位体的用途
CN101151246A (zh) * 2005-03-21 2008-03-26 欧加农股份有限公司 1-苄基吲哚-2-甲酰胺衍生物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DAVID T. CONNOR ET AL.: "Novel Benzothiophene-, Benzofuran-, and Naphthalenecarboxamidotetrazoles as Potential Antiallergy Agents", 《J. MED. CHEM.》 *
MARC NAZARE ET AL.: "Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral P1 substituents", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
MARC NAZARE ET AL.: "Probing the Subpockets of Factor Xa Reveals Two Binding Modes for Inhibitors Based on a 2-Carboxyindole Scaffold: A Study Combining Structure-Activity Relationship and X-ray Crystallography", 《J.MED.CHEM.》 *
MICHAEL BRANDS ET AL.: "Novel, selective indole-based ECE inhibitors: Lead optimization via solid-phase and classical synthesis", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
SUREYYA OLGEN ET AL.: "Synthesis and Antioxidant Properties of Novel N-Substituted Indole-2-carboxamide and Indole-3-acetamide Derivatives", 《ARCH. PHARM. PHARM. MED. CHEM.》 *

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106478662A (zh) * 2012-07-17 2017-03-08 武田药品工业株式会社 5‑ht3受体拮抗剂
US10407443B2 (en) 2012-07-17 2019-09-10 Takeda Pharmaceutical Company Limited 5-HT3 receptor antagonists
US10125145B2 (en) 2012-07-17 2018-11-13 Takeda Pharmaceutical Company Limited 5-HT3 receptor antagonists
CN104854087A (zh) * 2012-12-18 2015-08-19 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的吲哚羧酰胺衍生物
CN104854087B (zh) * 2012-12-18 2017-03-22 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的吲哚羧酰胺衍生物
CN104918946A (zh) * 2013-01-22 2015-09-16 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
US10047092B2 (en) 2013-03-14 2018-08-14 Janssen Pharmaceutica Nv Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
US11820770B2 (en) 2013-03-14 2023-11-21 Janssen Pharmaceutica Nv P2X7 modulators
US9604982B2 (en) 2013-03-14 2017-03-28 Janssen Pharmaceutica Nv P2X7 modulators
US9464084B2 (en) 2013-03-14 2016-10-11 Janssen Pharmaceutica Nv P2X7 modulators
CN110003200B (zh) * 2013-03-14 2021-11-26 詹森药业有限公司 P2x7调节剂
US10053463B2 (en) 2013-03-14 2018-08-21 Janssen Pharmaceutica Nv Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
US10053462B2 (en) 2013-03-14 2018-08-21 Janssen Pharmaceutica Nv P2X7 modulators
US10112937B2 (en) 2013-03-14 2018-10-30 Janssen Pharmaceutica Nv P2X7 modulators and methods of use
US12247027B2 (en) 2013-03-14 2025-03-11 Janssen Pharmaceutica Nv P2X7 modulators
US9540388B2 (en) 2013-03-14 2017-01-10 Janssen Pharmaceutica Nv P2X7 modulators
US10150765B2 (en) 2013-03-14 2018-12-11 Janssen Pharmaceutica Nv P2X7 modulators
CN105209464B (zh) * 2013-03-14 2019-01-01 詹森药业有限公司 P2x7调节剂
US10323032B2 (en) 2013-03-14 2019-06-18 Janssen Pharmaceutica Nv P2X7 Modulators
US11225478B2 (en) 2013-03-14 2022-01-18 Janssen Pharmaceutica Nv P2X7 modulators
CN110003200A (zh) * 2013-03-14 2019-07-12 詹森药业有限公司 P2x7调节剂
CN105209464A (zh) * 2013-03-14 2015-12-30 詹森药业有限公司 P2x7调节剂
US10703749B2 (en) 2013-03-14 2020-07-07 Janssen Pharmaceutica Nv P2X7 modulators
CN105636646B (zh) * 2013-07-17 2017-12-19 全球结核病药物研发联盟 氮杂吲哚化合物、其合成及其使用方法
CN105636646A (zh) * 2013-07-17 2016-06-01 全球结核病药物研发联盟 氮杂吲哚化合物、其合成及其使用方法
US10150766B2 (en) 2014-09-12 2018-12-11 Janssen Pharmaceutica Nv P2X7 modulators
US12338243B2 (en) 2014-09-12 2025-06-24 Janssen Pharmaceutica Nv P2X7 modulators
US10329306B2 (en) 2014-09-29 2019-06-25 Takeda Pharmaceutical Company Limited Crystalline form of 1-(1-methyl-1H-pyrazol-4-yl)-N-((IR,5S,7S)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1H-indole-3-carboxamide
US11993601B2 (en) 2018-09-28 2024-05-28 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
US11820766B2 (en) 2018-09-28 2023-11-21 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
US11597728B2 (en) 2018-09-28 2023-03-07 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
US11839663B2 (en) 2019-09-30 2023-12-12 Janssen Pharmaceutica Nv Radiolabelled MGL pet ligands
US12383635B2 (en) 2019-09-30 2025-08-12 Janssen Pharmaceutica Nv Radiolabelled MGL PET ligands
US11891387B2 (en) 2020-03-26 2024-02-06 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
CN116323581A (zh) * 2020-09-22 2023-06-23 苏州恩华生物医药科技有限公司 吲哚衍生物及其应用
CN116323581B (zh) * 2020-09-22 2025-05-30 苏州恩华生物医药科技有限公司 吲哚衍生物及其应用
WO2022062991A1 (zh) * 2020-09-22 2022-03-31 苏州恩华生物医药科技有限公司 吲哚衍生物及其应用
WO2023198199A1 (zh) * 2022-04-15 2023-10-19 先声再明医药有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂

Also Published As

Publication number Publication date
CA2691512A1 (en) 2009-02-19
SG183699A1 (en) 2012-09-27
EA020332B1 (ru) 2014-10-30
AU2008286946A1 (en) 2009-02-19
IL202550A0 (en) 2010-06-30
JP2015110566A (ja) 2015-06-18
EA200971085A1 (ru) 2010-06-30
WO2009023623A1 (en) 2009-02-19
KR20100066422A (ko) 2010-06-17
BRPI0812594A2 (pt) 2015-06-23
EP2185560A1 (en) 2010-05-19
EP2185560A4 (en) 2011-10-05
UA99729C2 (en) 2012-09-25
JP2010535816A (ja) 2010-11-25
CO6251319A2 (es) 2011-02-21
NZ582056A (en) 2012-08-31
AU2008286946B2 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
CN101778850A (zh) 杂芳基酰胺类似物
CN104844578B (zh) 5元杂环酰胺及相关的化合物
US20120190680A1 (en) Heteroaryl Amide Analogues
US8580812B2 (en) Heteroaryl amide analogues as P2X7 antagonists
CN101621931A (zh) 杂芳基酰胺衍生物
WO2009108551A2 (en) Heteroaryl amide analogues
HK1142599A (en) Heteroaryl amide analogues
HK1145841A (en) Heteroaryl amide analogues as p2x7 antagonists
HK1139005A (en) Heteroaryl amide derivatives
HK1142330B (en) 5-membered heterocyclic amides and related compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1142599

Country of ref document: HK

C05 Deemed withdrawal (patent law before 1993)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100714